中国中药(00570)跌超4%，截至发稿，跌4.57%，报2.09港元，成交额1129.92万港元。 本期由盈转亏主要原因为：中药配方颗粒业务受集采业务占比提高、市场竞争加剧等影响，收入规模及 盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加;及经调整溢利净额为扣除以下各项影响 后的溢利净额：商誉及相关资产组减值;及部分附属公司补缴税款。 消息面上，中国中药公布，预期集团截至2025年12月31日止年度由盈转亏，亏损净额区间预计约为人民 币3.50亿元至5亿元，上年同期溢利净额约为人民币2077万元；及本期经调整溢利净额同比下降45%至 55%，上年同期约为人民币6.355亿元。 ...

Core Viewpoint - China Traditional Chinese Medicine (00570) is expected to report a net loss for the fiscal year ending December 31, 2025, with losses projected between RMB 350 million and 500 million, a significant decline from a net profit of RMB 20.77 million in the same period last year [1] Group 1: Financial Performance - The adjusted net profit for the current period is expected to decrease by 45% to 55%, compared to approximately RMB 635.5 million in the previous year [1] - The company’s stock has dropped over 4%, currently trading at HKD 2.09, with a trading volume of HKD 11.2992 million [1] Group 2: Reasons for Loss - The transition from profit to loss is primarily attributed to the increased proportion of centralized procurement in the Chinese medicine formula granule business, leading to a decline in revenue scale and profitability [1] - Additional factors contributing to the loss include impairment of goodwill, impairment of intangible assets, and increased credit impairment [1] - The adjusted net profit excludes impacts from goodwill and related asset group impairments, as well as tax payments made by certain subsidiaries [1]

证券日报网讯 1月27日，片仔癀发布公告称，公司控股股东九龙江集团计划自2026年2月1日至7月31 日，以自有及自筹资金通过集中竞价增持公司A股，金额不低于3亿元且不超过5亿元，增持不设价格区 间，实施完成后12个月内不减持。 （文章来源：证券日报） ...

Group 1 - The company, Kunming Pharmaceutical Group, stated that it strictly adheres to laws, regulations, and regulatory requirements, and will fulfill information disclosure obligations in a timely manner if any matters meet the disclosure standards [2] - The stock price fluctuations of the listed company are influenced by multiple factors, including macroeconomic conditions, industry cycles, and market sentiment [2]

【导读】片仔癀控股股东拟首次增持公司股份 连续4个交易日市值跌破千亿元之后，片仔癀控股股东出手了，拟首次增持公司股份。 控股股东拟首次增持 片仔癀1月27日晚发布公告称，基于对公司未来持续稳定发展的信心和长期投资价值的认可，公司控股股东漳州市九龙江集 团有限公司（以下简称九龙江集团）计划自2026年2月1日起至2026年7月31日（即6个月内），以自有及自筹资金，通过上 海证券交易所交易系统以集中竞价方式增持公司股份，合计拟增持金额不低于3亿元（含）且不超过5亿元（含）。本次增 持计划不设定价格区间，将根据公司股票价格波动情况及资本市场整体趋势，择机逐步实施增持计划。 目前，九龙江集团总计持有片仔癀总股本的50.97%。 市值连续4天低于千亿元 2025年，上证指数上涨18.41%，但片仔癀股价逆市下跌20.04%。 1月22日，片仔癀市值跌破千亿元，之后公司股价继续下跌，至今已连续4个交易日市值低于千亿元，回落至2020年7月的水 平。 2025年前三季度，片仔癀实现营收74.72亿元，同比下降11.93%；净利润为21.29亿元，同比下降20.74%；扣非净利润为 18.91亿元，同比下降30.38%；经 ...

证券日报网讯 1月27日，昆药集团在互动平台回答投资者提问时表示，昆药集团财务共享中心成立于 2021年，整体运行成熟、稳定。 （文章来源：证券日报） ...

Core Viewpoint - The controlling shareholder of Pian Zai Huang plans to increase its stake in the company for the first time, indicating confidence in the company's future development and long-term investment value [2][6]. Group 1: Shareholder Actions - The controlling shareholder, Zhangzhou Jiulongjiang Group, intends to increase its holdings from February 1, 2026, to July 31, 2026, with a total investment of no less than 300 million yuan and no more than 500 million yuan [7]. - This share buyback will be executed through the Shanghai Stock Exchange's trading system without a set price range, depending on stock price fluctuations and overall market trends [7]. - Currently, Jiulongjiang Group holds 50.97% of Pian Zai Huang's total share capital [7]. Group 2: Market Performance - Pian Zai Huang's market value has fallen below 100 billion yuan for four consecutive trading days, reaching levels not seen since July 2020 [10]. - In 2025, while the Shanghai Composite Index rose by 18.41%, Pian Zai Huang's stock price declined by 20.04% [11]. - For the first three quarters of 2025, Pian Zai Huang reported revenue of 7.472 billion yuan, a year-on-year decrease of 11.93%, and a net profit of 2.129 billion yuan, down 20.74% [11]. - The company's cash flow from operating activities saw a significant decline of 62.53% year-on-year [11].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 【导读】片仔癀控股股东拟首次增持公司股份 中国基金报记者 卢鸰 连续4个交易日市值跌破千亿元之后，片仔癀控股股东出手了，拟首次增持公司股份。 控股股东拟首次增持 片仔癀1月27日晚发布公告称，基于对公司未来持续稳定发展的信心和长期投资价值的认可，公司控股 股东漳州市九龙江集团有限公司（以下简称九龙江集团）计划自2026年2月1日起至2026年7月31日（即6 个月内），以自有及自筹资金，通过上海证券交易所交易系统以集中竞价方式增持公司股份，合计拟增 持金额不低于3亿元（含）且不超过5亿元（含）。本次增持计划不设定价格区间，将根据公司股票价格 波动情况及资本市场整体趋势，择机逐步实施增持计划。 目前，九龙江集团总计持有片仔癀总股本的50.97%。 值得注意的是，片仔癀在公告标题中提示，这是控股股东首次增持公司股份。 市值连续4天低于千亿元 责任编辑：杨红卜 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 【导读】片仔癀控股股东拟首次增持公司股份 中国基金报记者 卢鸰 2025年 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The recent policy issued by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical and biotechnology index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.1 percentage points [11] - The report suggests focusing on high-quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin, as the pharmaceutical commercial sector is expected to see improved performance due to favorable policies [33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Among sub-sectors, pharmaceutical commerce rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] - The top five A-share stocks in the industry this week included *ST Changyao (+70.37%) and Hualan Biological Engineering (+32.21%) [22] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and industry structure [28] - A loan interest subsidy policy for small and micro enterprises in the pharmaceutical sector was announced, aimed at encouraging investment in manufacturing [28] Company Announcements - Significant announcements include the resignation of executives at various companies and performance forecasts indicating potential losses for some firms due to price reductions and demand declines [36]

董事会认为：集团本期由盈转亏主要原因为：中药配方颗粒业务受集采业务占比提高、市场竞争加剧等 影响，收入规模及盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加;及经调整溢利净额为 扣除以下各项影响后的溢利净额：商誉及相关资产组减值;及部分附属公司补缴税款。 中国中药(00570)发布公告，预期集团截至2025年12月31日止年度由盈转亏，亏损净额区间预计约为人 民币3.50亿元至5亿元，上年同期溢利净额约为人民币2077万元;及本期经调整溢利净额同比下降45%至 55%，上年同期约为人民币6.355亿元。 ...